10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.
The company has great information about it on their website with promising statisics.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.
The company has great information about it on their website with promising statisics.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.